Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 5
Treatment-assignment count: 0
Stratification count: 1
Trial Selection Rising
CLDN18.2 expression
gastric cancer · Immune Checkpoint Inhibitor
CLDN18.2 expression is flagged as trial selection rising because public trials show inclusion required evidence in 7 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 1
Common snippets: PD-L1 CPS ≥ 1
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 1
Recent signals: 1
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT03505320 | https://clinicaltrials.gov/study/NCT07432295 | https://clinicaltrials.gov/study/NCT07673887 | https://clinicaltrials.gov/study/NCT07431281 | https://clinicaltrials.gov/study/NCT06901531 | https://clinicaltrials.gov/study/NCT07270991 | https://clinicaltrials.gov/study/NCT05365581